Rokit Healthcare, a pioneer in artificial intelligence (AI) powered hyper-personalized long-term regeneration platforms, announced on Wednesday that it has secured a crucial patent registration for AI-based cartilage regeneration in the United Arab Emirates (UAE). The company is set to collaborate with major UAE healthcare investors to target the Middle Eastern joint regeneration market, estimated at 1 trillion KRW (about 682 million USD).
This achievement, following the successful commercialization of cartilage regeneration in South America, is expected to revolutionize the Middle Eastern healthcare landscape, shifting focus from traditional surgeries to regenerative medicine.
The patented technology utilizes AI to precisely analyze cartilage damage and automatically design and produce patient-specific bio-inks and scaffolds.
This innovation gives Rokit Healthcare a significant competitive edge in the UAE and Middle Eastern markets, creating a formidable technological barrier. The company plans to aggressively pursue local clinical trials and commercialization under this patent protection.
Strategic alliance with leading local healthcare group paves way for demonstration and commercialization
Last month, Rokit Healthcare strengthened its foothold in the Middle Eastern cartilage market by signing a strategic partnership with a major local healthcare provider linked to the UAE sovereign wealth fund, initiating collaboration on AI cartilage regeneration.
The partners aim to swiftly introduce Rokit Healthcare’s regenerative treatment platform to local hospitals and jointly promote regenerative medicine treatment models, with the goal of inclusion in standard regional treatment guidelines.
The UAE patent registration is crucial as it bolsters local rights protection and business stability for the technology, in conjunction with ongoing cartilage regeneration demonstration projects with the region’s largest healthcare company.
This development is expected to enhance the credibility of Rokit Healthcare’s technological prowess and business differentiation as it enters the Middle Eastern market.
1 Trillion KRW Market Projected By 2030 as Middle East Enters Structural Growth Phase
Rokit Healthcare is targeting the Middle East due to its explosive market potential. The Middle East and Africa (MEA) region is experiencing surging demand for joint disease treatments, driven by an aging population, rising obesity rates, and increased sports participation. Research and Markets projects the region’s osteoarthritis treatment market to grow at 6.5% annually, reaching approximately 760 million USD by 2030.
With an estimated 100,000 new cartilage damage patients annually, Rokit Healthcare’s regenerative treatment solution offers a promising alternative to address unmet needs in this vast market, potentially reducing side effects and reoperation rates associated with traditional artificial joint replacements.
A Rokit Healthcare spokesperson stated that the Middle East represents a land of opportunity, with a rapidly growing population of joint disease patients and a lack of fundamental regenerative treatment solutions. Leveraging the UAE patent and partnership with major local healthcare investors, it aims to reshape the Middle Eastern joint treatment landscape around regenerative medicine and establish itself as a global leader in AI-driven long-term regeneration healthcare.